Sami Corwin
Stock Analyst at William Blair
(0.10)
# 4,411
Out of 5,044 analysts
11
Total ratings
16.67%
Success rate
-20.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sami Corwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics | Initiates: Outperform | n/a | $7.61 | - | 1 | Aug 20, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | n/a | $24.22 | - | 1 | Jun 20, 2025 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Outperform | $65 | $34.77 | +86.94% | 1 | May 28, 2025 | |
| NKTX Nkarta | Downgrades: Market Perform | n/a | $2.31 | - | 1 | May 15, 2025 | |
| APLT Applied Therapeutics | Downgrades: Market Perform | n/a | $1.30 | - | 1 | Dec 23, 2024 | |
| TNYA Tenaya Therapeutics | Initiates: Outperform | n/a | $1.56 | - | 1 | Jun 10, 2024 | |
| NGNE Neurogene | Initiates: Outperform | n/a | $30.96 | - | 1 | Mar 21, 2024 | |
| MESO Mesoblast | Downgrades: Market Perform | n/a | $16.73 | - | 1 | Aug 4, 2023 | |
| CRSP CRISPR Therapeutics AG | Reinstates: Outperform | $75 | $64.17 | +16.88% | 1 | May 30, 2023 | |
| LEGN Legend Biotech | Initiates: Market Perform | n/a | $32.57 | - | 1 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $66 | $70.00 | -5.71% | 1 | Oct 27, 2021 |
Kyverna Therapeutics
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $7.61
Upside: -
Sarepta Therapeutics
Jun 20, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $24.22
Upside: -
Ultragenyx Pharmaceutical
May 28, 2025
Initiates: Outperform
Price Target: $65
Current: $34.77
Upside: +86.94%
Nkarta
May 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.31
Upside: -
Applied Therapeutics
Dec 23, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.30
Upside: -
Tenaya Therapeutics
Jun 10, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.56
Upside: -
Neurogene
Mar 21, 2024
Initiates: Outperform
Price Target: n/a
Current: $30.96
Upside: -
Mesoblast
Aug 4, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $16.73
Upside: -
CRISPR Therapeutics AG
May 30, 2023
Reinstates: Outperform
Price Target: $75
Current: $64.17
Upside: +16.88%
Legend Biotech
May 25, 2023
Initiates: Market Perform
Price Target: n/a
Current: $32.57
Upside: -
Oct 27, 2021
Initiates: Outperform
Price Target: $66
Current: $70.00
Upside: -5.71%